INS and type 2 diabetes mellitus: Different SGLT‐2is have undergone extensive evaluation in various cardiovascular outcome trials (CVOTs); however, as these studies only address patients with T2DM, the late‐breaking question has been if SGLT‐2is will confer equal or varying benefits when used as an adjunct treatment to insulin in T1DM.